Zacks Research Has Positive Forecast for HALO Q3 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Zacks Research boosted their Q3 2026 earnings estimates for shares of Halozyme Therapeutics in a report released on Thursday, August 27th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $2.06 per share for the quarter, up from their prior estimate of $1.95. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $7.77 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2027 earnings at $2.16 EPS.

Several other research analysts have also recently issued reports on HALO. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Citizens Jmp raised their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $107.72 on Wednesday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $109.66. The stock has a 50 day moving average price of $88.52 and a two-hundred day moving average price of $75.13. The company has a market capitalization of $12.23 billion, a P/E ratio of 32.16, a PEG ratio of 0.43 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 32,478 shares of company stock worth $3,076,604. Company insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of the business. MidFirst Bank bought a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $27,000. Larson Financial Group LLC boosted its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $28,000. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Halozyme Therapeutics during the second quarter valued at $30,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.